JP2023529124A5 - - Google Patents
Info
- Publication number
- JP2023529124A5 JP2023529124A5 JP2022573756A JP2022573756A JP2023529124A5 JP 2023529124 A5 JP2023529124 A5 JP 2023529124A5 JP 2022573756 A JP2022573756 A JP 2022573756A JP 2022573756 A JP2022573756 A JP 2022573756A JP 2023529124 A5 JP2023529124 A5 JP 2023529124A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- adenovirus
- adenovirus vector
- coronavirus
- vector according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063032815P | 2020-06-01 | 2020-06-01 | |
| US63/032,815 | 2020-06-01 | ||
| US202063051103P | 2020-07-13 | 2020-07-13 | |
| US63/051,103 | 2020-07-13 | ||
| US202163162417P | 2021-03-17 | 2021-03-17 | |
| US63/162,417 | 2021-03-17 | ||
| PCT/US2021/035239 WO2021247567A1 (en) | 2020-06-01 | 2021-06-01 | Coronavirus vaccine constructs and methods of making and using same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023529124A JP2023529124A (ja) | 2023-07-07 |
| JP2023529124A5 true JP2023529124A5 (enExample) | 2024-06-07 |
| JP7895039B2 JP7895039B2 (ja) | 2026-07-27 |
Family
ID=78829898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022573756A Active JP7895039B2 (ja) | 2020-06-01 | 2021-06-01 | コロナウイルスワクチンコンストラクトおよびこれを作製し使用する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230227848A1 (enExample) |
| EP (1) | EP4157347A4 (enExample) |
| JP (1) | JP7895039B2 (enExample) |
| KR (1) | KR20230033650A (enExample) |
| AU (1) | AU2021285823A1 (enExample) |
| CA (1) | CA3180064A1 (enExample) |
| WO (1) | WO2021247567A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250064919A1 (en) * | 2022-01-06 | 2025-02-27 | Board Of Regents, The University Of Texas System | A SARS-COV-2 Human Parainfluenza Virus Type 3-Vectored Vaccine |
| AU2023216258A1 (en) * | 2022-02-02 | 2024-08-01 | Washington University | Omicron coronavirus vaccine constructs and methods of making and using same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2325298B1 (en) * | 2008-03-04 | 2016-10-05 | The Trustees Of The University Of Pennsylvania | SIMIAN ADENOVIRUSES SAdV-36, -42.1, -42.2, AND -44 AND USES THEREOF |
| WO2018081318A1 (en) * | 2016-10-25 | 2018-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
| CN111088283B (zh) * | 2020-03-20 | 2020-06-23 | 苏州奥特铭医药科技有限公司 | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 |
-
2021
- 2021-06-01 JP JP2022573756A patent/JP7895039B2/ja active Active
- 2021-06-01 EP EP21817848.1A patent/EP4157347A4/en active Pending
- 2021-06-01 KR KR1020227044997A patent/KR20230033650A/ko active Pending
- 2021-06-01 WO PCT/US2021/035239 patent/WO2021247567A1/en not_active Ceased
- 2021-06-01 AU AU2021285823A patent/AU2021285823A1/en active Pending
- 2021-06-01 CA CA3180064A patent/CA3180064A1/en active Pending
- 2021-06-01 US US18/007,677 patent/US20230227848A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023512519A5 (enExample) | ||
| CN113666990B (zh) | 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用 | |
| EP3804751A2 (en) | Adenovirus carrier vaccine used for preventing sars-cov-2 infection | |
| CN111088283A (zh) | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 | |
| JP2017503482A5 (enExample) | ||
| JP2020511940A5 (enExample) | ||
| Ramirez et al. | Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration | |
| WO2021224946A1 (en) | Coronavirus vaccine through nasal immunization | |
| CN104302319B (zh) | 包含突变的糖蛋白c的重组马疱疹病毒-1疫苗及其用途 | |
| WO2023151173A1 (zh) | 表达SARS-CoV-2奥密克戎突变株病毒抗原肽的核酸序列及其应用 | |
| JP2025508676A5 (enExample) | ||
| WO2021220246A1 (en) | Recombinant sars-cov-2 polypeptides and uses | |
| WO2021207848A1 (en) | Mers-cov vaccine | |
| JP2021518152A5 (enExample) | ||
| JP2009544303A5 (enExample) | ||
| JP7642608B2 (ja) | ハンタウイルス抗原性組成物 | |
| CN116888139A (zh) | 诱导高水平i型干扰素的新型复制缺陷型甲型流感病毒 | |
| WO2022037095A1 (zh) | 优化的表达新型冠状病毒抗原的核苷酸序列及其应用 | |
| CN118126141B (zh) | 一种表达猪瘟病毒突变的全长e2蛋白的重组伪狂犬病毒株及应用 | |
| CN116925195B (zh) | 一种基于新型冠状病毒的mRNA疫苗 | |
| JP2011088864A (ja) | インフルエンザウイルスに対するベクターワクチン | |
| WO2019100147A1 (en) | Synthetic hemagglutinin as universal vaccine against infection by type b influenza viruses (ibv) | |
| JP2023529836A5 (enExample) | ||
| KR102616012B1 (ko) | 당화된 돼지 인터페론-알파를 발현하는 재조합 베큘로바이러스 | |
| US12128097B2 (en) | AD35-vectored immunogenic composition for SARS-COV-2 infection |